298 related articles for article (PubMed ID: 27794407)
1. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
2. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
3. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
[TBL] [Abstract][Full Text] [Related]
5. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
6. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
7. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
[TBL] [Abstract][Full Text] [Related]
8. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
9. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL
J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557
[TBL] [Abstract][Full Text] [Related]
10. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
12. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
[TBL] [Abstract][Full Text] [Related]
13. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Boyle TA; Masago K; Ellison KE; Yatabe Y; Hirsch FR
Clin Lung Cancer; 2015 Mar; 16(2):106-11. PubMed ID: 25467930
[TBL] [Abstract][Full Text] [Related]
14. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Shan L; Lian F; Guo L; Qiu T; Ling Y; Ying J; Lin D
PLoS One; 2015; 10(3):e0120422. PubMed ID: 25742289
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
16. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
Cha YJ; Lee JS; Kim HR; Lim SM; Cho BC; Lee CY; Shim HS
PLoS One; 2014; 9(7):e103333. PubMed ID: 25058391
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
Tarigopula A; Ramasubban G; Chandrashekar V; Govindasami P; Chandran C
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1288. PubMed ID: 32881404
[TBL] [Abstract][Full Text] [Related]
18. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
[TBL] [Abstract][Full Text] [Related]
19. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
20. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.
McLeer-Florin A; Moro-Sibilot D; Melis A; Salameire D; Lefebvre C; Ceccaldi F; de Fraipont F; Brambilla E; Lantuejoul S
J Thorac Oncol; 2012 Feb; 7(2):348-54. PubMed ID: 22071784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
